Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244636 | 1.00 | PTGS2 (0.34) | PTGS2PTGS1GSR | |
| SCHEMBL1244648 | 1.00 | PTGS2 (0.34) | PTGS2PTGS1GSR | |
| SCHEMBL1242354 | 0.95 | PTGS2 (0.37) | PTGS2PTGS1GSR | |
| SCHEMBL1242135 | 0.95 | PTGS2 (0.37) | PTGS2PTGS1GSR | |
| SCHEMBL17554625 | 0.91 | GSR (0.30) | GSR | |
| SCHEMBL1243887 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1GSR | |
| SCHEMBL7448724 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1GSR | |
| SCHEMBL4370859 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1GSR | |
| SCHEMBL11782405 | 0.84 | CA12 (0.35) | PTGS2PTGS1 | |
| SCHEMBL8267033 | 0.82 | ALDH1A1 (0.35) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | disclosed |
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | NICOX S.A. (FR) | 2024-05-14 | — | — | US | disclosed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3833395-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | Nicox S.A. (FR) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020030489-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2020-02-13 | — | — | WO | disclosed |
| CN-106795099-B | prodrugs and compositions for the treatment of hypertension and cardiovascular disease | 南京奥昭生物科技有限公司 | 2019-11-26 | — | — | CN | disclosed |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| WO-2018224419-A1 | NITRIC OXIDE DONATING ISOMANNIDE DERIVATIVES | NICOX S.A. (FR) | 2018-12-13 | — | — | WO | disclosed |
| US-10093696-B2 | Nitric oxide donating carnosine compounds | NICOX SCIENCE IRELAND (IE) | 2018-10-09 | — | — | US | disclosed |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076246-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076247-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076245-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1711457-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1711454-A4 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2007-04-04 | — | — | EP | disclosed |
| EP-1711454-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711457-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070874-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070868-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | PDE5A, PDE3A, PDE3B | PTGS2 55/4885PTGS1 42/4885GSR 563/4885 |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | PTGS2 9/4885PTGS1 6/4885GSR 132/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | PTGS2 1456/4885PTGS1 1479/4885GSR 1878/4885 |
| US-10093696-B2 | Nitric oxide donating carnosine compounds | NOS1, NOS2, NOS3 | PTGS2 62/4885PTGS1 19/4885GSR 40/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | PTGS2 9/4885PTGS1 6/4885GSR 132/4885 |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | PTGS2 43/4885PTGS1 36/4885GSR 745/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | PTGS2 42/4885PTGS1 35/4885GSR 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.